SANTA MONICA, Calif.--(BUSINESS WIRE)--
Kite Pharma, Inc. (Nasdaq:KITE) has announced the appointment of
Christine Cassiano as Senior Vice President of Corporate Communications
and Investor Relations. She will also sit on the company's Executive
Committee. In this new position, Cassiano will be responsible for
transforming Kite's communications function to keep pace with the
company's expanding pipeline of chimeric antigen receptor (CAR) and
T-cell receptor (TCR) product candidates to treat both hematological
(blood-based) and solid cancers.
This Smart News Release features multimedia. View the full release here:
Christine Cassiano, SVP, Corporate Communications & Investor Relations, Kite Pharma (Photo: Business Wire)
"Christine arrives at a key inflection point for Kite as we advance our
CAR-T and TCR pipeline toward key company milestones, including our BLA
submission for KTE-C19 with the FDA, and evolve Kite into a commercial
organization," said Arie Belldegrun, M.D., FACS, Chairman, President and
Chief Executive Officer of Kite. "Christine's progressive communications
approach and vast experience will allow us to enhance our education of
key audiences on the changing cancer treatment paradigm, the value of
CAR-T therapy, and our role in its innovation."
With a dual background in investor and public relations, Christine has
an extensive history developing innovative approaches that advance
communications in corporate positioning, issues management, employee
engagement, commercialization and investor relations.
"My enthusiasm for Kite's groundbreaking research goes beyond my
professional drive to innovate healthcare communications - it is also
deeply personal," said Cassiano. "Like many who have lost a loved one to
cancer, I understand first-hand the optimism and promise scientific
progress offers to patients whose lives depend on significant
breakthroughs in care. I am eager to further the understanding of Kite's
role in advancing breakthrough therapies for cancer."
Cassiano was most recently Head of Healthcare for the W2O Group, an
integrated healthcare marketing and communications consulting firm. She
previously co-founded ARC2 Communications & Media, a boutique agency
that developed groundbreaking platforms for some of the largest
companies in healthcare. Her more than 20-year career includes multiple
product launches across various therapeutic areas such as Botox®/Botox®
Cosmetic (onabotulinumtoxinA), Prolia® (denosumab), Abraxane®
(paclitaxel) and Lumigan® (bimatoprost ophthalmic solution)
as well as leading global efforts as Senior Vice President &
Co-Director, Healthcare at Hill + Knowlton Strategies. Cassiano has held
senior communications roles at biotechnology and pharmaceutical
companies such as Amgen, Allergan and Abraxis BioScience. Some of
Cassiano's career achievements include a SABRE Silver Anvil award for
the launch of Botox® Cosmetic (Allergan), an In2 SABRE Award
for the Most Innovative Brand/Agency Collaboration (Pfizer/ARC2), and PR
Week's 40 Under 40.
About Kite Pharma
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged
in the development of novel cancer immunotherapy products, with a
primary focus on engineered autologous cell therapy (eACT™) designed to
restore the immune system's ability to recognize and eradicate tumors.
Kite is based in Santa Monica, CA. For more information on Kite Pharma,
please visit www.kitepharma.com.
Sign up to follow @KitePharma on Twitter at www.twitter.com/kitepharma.
Kite Pharma, Inc. Forward-Looking Statements
This press release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. The press release may, in some cases, use terms such as
"predicts," "believes," "potential," "proposed," "continue,"
"estimates," "anticipates," "expects," "plans," "intends," "may,"
"could," "might," "will," "should" or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Forward-looking statements include
statements regarding intentions, beliefs, projections, outlook, analyses
or current expectations concerning, among other things: submitting a
Biologics License Application (BLA) for KTE-C19 with the U.S. Food and
Drug Administration (FDA), commercially launching KTE-C19 and the
ability to advance additional product candidates. Various factors may
cause differences between Kite's expectations and actual results as
discussed in greater detail in Kite's filings with the Securities and
Exchange Commission, including without limitation in its Form 10-Q for
the quarter ended June 30, 2016. Any forward-looking statements that are
made in this press release speak only as of the date of this press
release. Kite assumes no obligation to update the forward-looking
statements whether as a result of new information, future events or
otherwise, after the date of this press release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160929006258/en/
Kite Pharma, Inc.
Communications & Investor Relations
VP, Investor Relations
Source: Kite Pharma, Inc.
News Provided by Acquire Media